Hyperpigmentation

Henrick S

doi:10.37421/2576-3857.2021.06.130

Image Article - (2021) Volume 6, Issue 1

Hyperpigmentation

^*Correspondence: Henrick Stain, Department of Medical Oncology, Auburn University, United States, Email:

Author information

¹Department of Medical Oncology, Auburn University, United States

Received: 10-Jan-2021 Published: 10-Feb-2021 , DOI: 10.37421/2576-3857.2021.06.130
Citation: Stain H. Hyperpigmentation. J Oncol Med & Pract 6 (2021): 130
Copyright: ©2021 Stain H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Clinical Image

In contrast with palmoplantar erythrodysesthesia (hand-foot syndrome), hematological toxicity, and neurotoxicity, skin pigmentation disorders secondary to infusion of Pegylated liposomal doxorubicin (PLD) are relatively uncommon side effects.

This is a 82-year-old patient treated with a PLD-based palliative regimen for metastatic ovarian cancer at a dosage of 30 mg/m2 once every 35 days (1-5). After six cycles of chemotherapy, she showed dorsal hyperpigmentation. After the product stopped, this skin toxicity steadily regressed after.

References

Desai S. Hyperpigmentation Therapy: A Review. J Clin Aesthet Dermatol (2014) 7: 13-17.
Hollinger JC. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol (2018) 11: 28-37.
Davis EC, Callender VD. Postinflammatory Hyperpigmentation. J Clin Aesthet Dermatol (2010) 3: 20-31.
Sakar R, Arora P, Garg V. Cosmeceuticals for Hyperpigmentation: What is Available?. J Cutan Aesthet Surg (2013) 6: 4-11.
Krobotova LN. Hyperpigmentation: types, diagnostics and targeted treatment options. J Eur Acad Dermatol Venereol 1(2013): 2-4.